TWI465448B - Cgrp受體拮抗劑 - Google Patents

Cgrp受體拮抗劑 Download PDF

Info

Publication number
TWI465448B
TWI465448B TW099135091A TW99135091A TWI465448B TW I465448 B TWI465448 B TW I465448B TW 099135091 A TW099135091 A TW 099135091A TW 99135091 A TW99135091 A TW 99135091A TW I465448 B TWI465448 B TW I465448B
Authority
TW
Taiwan
Prior art keywords
group
hydrogen
pyridin
cyclohepta
tetrahydro
Prior art date
Application number
TW099135091A
Other languages
English (en)
Chinese (zh)
Other versions
TW201118096A (en
Inventor
羅光林
吉尼M 杜包基
約翰E 馬可
Original Assignee
必治妥美雅史谷比公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43242489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI465448(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 必治妥美雅史谷比公司 filed Critical 必治妥美雅史谷比公司
Publication of TW201118096A publication Critical patent/TW201118096A/zh
Application granted granted Critical
Publication of TWI465448B publication Critical patent/TWI465448B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW099135091A 2009-10-14 2010-10-14 Cgrp受體拮抗劑 TWI465448B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25147709P 2009-10-14 2009-10-14

Publications (2)

Publication Number Publication Date
TW201118096A TW201118096A (en) 2011-06-01
TWI465448B true TWI465448B (zh) 2014-12-21

Family

ID=43242489

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099135091A TWI465448B (zh) 2009-10-14 2010-10-14 Cgrp受體拮抗劑

Country Status (35)

Country Link
US (2) US8314117B2 (enExample)
EP (1) EP2488512B1 (enExample)
JP (3) JP5836279B2 (enExample)
KR (3) KR101755742B1 (enExample)
CN (1) CN102656159B (enExample)
AR (2) AR078638A1 (enExample)
AU (1) AU2010306954B2 (enExample)
BR (1) BR112012008828B1 (enExample)
CA (2) CA2968176C (enExample)
CL (1) CL2012000925A1 (enExample)
CO (1) CO6460732A2 (enExample)
CY (1) CY2022023I1 (enExample)
DK (1) DK2488512T3 (enExample)
EA (1) EA020409B1 (enExample)
ES (1) ES2441192T3 (enExample)
FR (1) FR22C1044I2 (enExample)
HR (1) HRP20140111T1 (enExample)
HU (1) HUS2200033I1 (enExample)
IL (1) IL219120A (enExample)
LT (1) LTC2488512I2 (enExample)
LU (1) LUC00272I2 (enExample)
MX (1) MX2012004182A (enExample)
NL (1) NL301187I2 (enExample)
NO (1) NO2022033I1 (enExample)
NZ (1) NZ599281A (enExample)
PE (1) PE20121137A1 (enExample)
PL (1) PL2488512T3 (enExample)
PT (1) PT2488512E (enExample)
RS (1) RS53149B (enExample)
SI (1) SI2488512T1 (enExample)
SM (1) SMT201400019B (enExample)
TN (1) TN2012000139A1 (enExample)
TW (1) TWI465448B (enExample)
WO (1) WO2011046997A1 (enExample)
ZA (1) ZA201203452B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) * 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) * 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
HUE034936T2 (hu) * 2012-02-27 2018-03-28 Bristol Myers Squibb Co N-(5S,6S,9R)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5H-ciklohepta[B-]piridin-9-il-4- (2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-IL)piperidin-1-karboxilát, hemiszulfát só
WO2013169563A1 (en) * 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
TW201718574A (zh) * 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
KR20200135465A (ko) 2018-03-25 2020-12-02 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. Cgrp 관련 장애를 위한 리메게판트
CN114805206B (zh) * 2021-01-27 2025-01-14 奥锐特药业(天津)有限公司 高光学纯度瑞美吉泮中间体的工业化制备方法
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び/又は発生の低減
US20250109188A1 (en) 2021-08-24 2025-04-03 Cgrp Diagnostics Gmbh Preventative treatment of migraine
CN115850266A (zh) * 2021-09-26 2023-03-28 奥锐特药业(天津)有限公司 瑞美吉泮新晶型及其制备方法
CN116554164B (zh) * 2022-01-27 2025-10-03 奥锐特药业(天津)有限公司 一种瑞美吉泮的制备方法
WO2023175632A1 (en) * 2022-03-17 2023-09-21 Msn Laboratories Private Limited, R&D Center Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof
CN116478211B (zh) * 2022-04-19 2023-10-24 石家庄迪斯凯威医药科技有限公司 一种新型cgrp受体拮抗剂及其用途
CN115060824B (zh) * 2022-06-14 2024-03-12 浙江宏元药业股份有限公司 一种瑞米吉泮中间体对映异构体杂质的液相色谱检测方法
CN117466893A (zh) * 2022-07-29 2024-01-30 熙源安健医药(上海)有限公司 吡啶并环庚烷类衍生物及其制备方法和用途
CN115677694A (zh) * 2022-11-30 2023-02-03 南通常佑药业科技有限公司 一种瑞美吉泮的合成方法
WO2024180562A1 (en) * 2023-03-02 2024-09-06 Natco Pharma Limited A process for the preparation of pure crystalline rimegepant and its salts thereof
CN116768938B (zh) * 2023-05-17 2025-11-11 南京艾德凯腾生物医药有限责任公司 一种铁催化剂及瑞美吉泮中间体的制备方法
WO2025061177A1 (zh) * 2023-09-21 2025-03-27 成都康弘药业集团股份有限公司 一种治疗cgrp相关障碍的小分子药物
CN117486798B (zh) * 2023-12-21 2025-02-07 南京威凯尔生物医药科技有限公司 一种瑞美吉泮中间体盐酸盐的晶型及其制备方法
WO2025193980A2 (en) * 2024-03-13 2025-09-18 CNS Biosciences, Inc. Method of treating neuropathic pain using an anti-cgrp inhibitor
CN119707808B (zh) * 2024-12-23 2025-12-05 上海彩迩文生化科技有限公司 一种制备cgrp受体拮抗剂中间体的方法
CN119977885A (zh) * 2025-04-15 2025-05-13 常州制药厂有限公司 (5S,6S,9R)-5-氨基-6-(2,3-二氟苯基)-6,7,8,9-四氢-5H-环庚[b]吡啶-9-醇L-酒石酸盐及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044504A1 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
WO2006047196A2 (en) * 2004-10-22 2006-05-04 Merck & Co., Inc. Cgrp receptor antagonists
EP1726590A1 (en) * 2004-03-05 2006-11-29 Banyu Pharmaceutical Co., Ltd. Cycloalkanopyridine derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US20060084708A1 (en) 2004-10-14 2006-04-20 Bayer Materialscience Llc Rigid foams with good insulation properties and a process for the production of such foams
CN101421267B (zh) 2006-04-10 2011-10-19 默沙东公司 制备吡啶杂环cgrp拮抗剂中间体的方法
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1726590A1 (en) * 2004-03-05 2006-11-29 Banyu Pharmaceutical Co., Ltd. Cycloalkanopyridine derivative
WO2006044504A1 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
WO2006047196A2 (en) * 2004-10-22 2006-05-04 Merck & Co., Inc. Cgrp receptor antagonists

Also Published As

Publication number Publication date
AU2010306954A1 (en) 2012-05-03
LTC2488512I2 (enExample) 2025-03-10
NZ599281A (en) 2013-01-25
TN2012000139A1 (en) 2013-09-19
HK1169390A1 (en) 2013-01-25
LTPA2022516I1 (enExample) 2022-08-25
RS53149B (sr) 2014-06-30
EP2488512B1 (en) 2013-11-27
TW201118096A (en) 2011-06-01
AR078638A1 (es) 2011-11-23
JP2017125054A (ja) 2017-07-20
PE20121137A1 (es) 2012-08-30
AR110069A2 (es) 2019-02-20
BR112012008828B1 (pt) 2021-11-23
SMT201400019B (it) 2014-05-07
ZA201203452B (en) 2014-10-29
PL2488512T3 (pl) 2014-04-30
WO2011046997A1 (en) 2011-04-21
EP2488512A1 (en) 2012-08-22
CN102656159B (zh) 2015-07-01
CA2777518A1 (en) 2011-04-21
MX2012004182A (es) 2012-05-29
JP2013508281A (ja) 2013-03-07
KR20180080343A (ko) 2018-07-11
FR22C1044I1 (fr) 2022-09-30
CL2012000925A1 (es) 2012-08-31
EA020409B1 (ru) 2014-10-30
KR20170081737A (ko) 2017-07-12
KR101990755B1 (ko) 2019-06-18
US20130053570A1 (en) 2013-02-28
FR22C1044I2 (fr) 2023-11-17
JP2015163625A (ja) 2015-09-10
CY2022023I2 (el) 2023-01-05
JP6258537B2 (ja) 2018-01-10
ES2441192T3 (es) 2014-02-03
HRP20140111T1 (hr) 2014-03-14
JP6109874B2 (ja) 2017-04-05
HUS2200033I1 (hu) 2022-08-28
NL301187I2 (nl) 2022-08-04
SI2488512T1 (sl) 2014-02-28
BR112012008828A2 (pt) 2020-09-15
IL219120A0 (en) 2012-06-28
KR101755742B1 (ko) 2017-07-07
US20110251223A1 (en) 2011-10-13
CA2777518C (en) 2017-07-04
CY2022023I1 (el) 2023-01-05
DK2488512T3 (en) 2014-02-24
CA2968176A1 (en) 2011-04-21
KR101875353B1 (ko) 2018-07-05
KR20120087940A (ko) 2012-08-07
CO6460732A2 (es) 2012-06-15
CN102656159A (zh) 2012-09-05
NO2022033I1 (no) 2022-07-22
JP5836279B2 (ja) 2015-12-24
AU2010306954B2 (en) 2016-05-26
EA201270561A1 (ru) 2012-12-28
US8314117B2 (en) 2012-11-20
PT2488512E (pt) 2014-02-24
LUC00272I2 (enExample) 2025-05-12
CA2968176C (en) 2019-11-26
IL219120A (en) 2016-12-29

Similar Documents

Publication Publication Date Title
TWI465448B (zh) Cgrp受體拮抗劑
CA2778886C (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
JP5421985B2 (ja) Cgrp受容体アンタゴニスト
CA2810696C (en) Pyrazoloquinoline compound
CN102395589A (zh) 稠合吡咯并吡啶衍生物
AU2009295231A1 (en) Azaindole derivatives as CRTH2 receptor antagonists
US20230027198A1 (en) Inhibitors of enl/af9 yeats
US7470680B2 (en) Constrained compounds as CGRP-receptor antagonists
HK1169390B (en) Cgrp receptor antagonists
JP2025541798A (ja) Ccr6阻害剤としてのスルホニル誘導体